{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mendler JH"],"funding":["NCI NIH HHS"],"pagination":["3109-18"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3732007"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(25)"],"pubmed_abstract":["<h4>Purpose</h4>To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures.<h4>Patients and methods</h4>Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays.<h4>Results</h4>RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated wi"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures."],"pmcid":["PMC3732007"],"funding_grant_id":["CA129657","CA101140","U24 CA114725","R21 CA129657","CA16058","CA114725","CA33601","CA31946","U10 CA031946","P30 CA016058","CA140158","U10 CA077658","U10 CA101140","CA77658","U10 CA033601","P50 CA140158"],"pubmed_authors":["Kolitz JE","Radmacher MD","Mendler JH","Whitman SP","Maharry K","Becker H","Moore JO","Schwind S","Khalife J","Wetzler M","Larson RA","Mrozek K","Carter TH","Nicolet D","Metzeler KH","Bloomfield CD","Carroll AJ","Kohlschmidt J","Powell BL","Marcucci G","Baer MR","Caligiuri MA"],"additional_accession":[]},"is_claimable":false,"name":"RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.","description":"<h4>Purpose</h4>To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures.<h4>Patients and methods</h4>Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations. Gene/microRNA expression profiles were derived using microarrays.<h4>Results</h4>RUNX1 mutations were found in 8% and 16% of younger and older patients, respectively (P = .02). They were associated wi","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Sep","modification":"2026-05-29T15:44:38.214Z","creation":"2019-03-27T01:13:59Z"},"accession":"S-EPMC3732007","cross_references":{"pubmed":["22753902"],"doi":["10.1200/jco.2011.40.6652","10.1200/JCO.2011.40.6652"]}}